Siddhartha Singh (Sid) 🚀

➠ Led the strategic and innovation efforts for Enfamil, a portfolio valued at £2.0 billion, renowned for its strong equity across North America, Latin America, and ASEAN, achieving a 5% CAGR in revenue. ➠ Contributed to a 100 basis points increase in company operating profit (COP) for 2022 and 2023 through targeted strategy execution and operational efficiencies. ➠ Developed and implemented a comprehensive 5-year innovation strategy focusing on liquid expansion, enhanced immunity offerings, and supply chain optimization. ➠ Directed the successful launch of the integrated global campaign "5 Year Brain Advantage," driving brand awareness and consumer engagement. ➠ Designed a sustainability roadmap emphasizing product pipeline innovation, packaging advancements, and societal impact initiatives to align with corporate environmental and social responsibility goals.

➠ Established operational excellence across the business, leading a team of five to drive efficiency and effectiveness. ➠ Developed and implemented a global success model that streamlined brand marketing, media, CRM, medical channels, and trade marketing, creating a standardized benchmark for regional and national strategies. ➠ Led the operationalization of a five-year strategic plan, utilizing a global scorecard to monitor and evaluate progress in top five markets contributing to 80% of revenue. ➠ Chaired the Global Marketing Excellence Committee, creating a 21st-century Marketing Academy to enhance talent development and retention. ➠ Defined and implemented a new global brand purpose and strategic framework to align marketing and business objectives. ➠ Strengthened external risk management by designing a framework for engagement with healthcare professionals (HCPs), regulators, and NGOs to ensure compliance and mitigate potential risks.

➠ Directed the management of a £138 million portfolio, overseeing full P&L accountability, brand equity enhancement, medical marketing initiatives, and CRM strategies. ➠ Revitalized business performance through strategic interventions across media, medical, trade, and e-commerce channels, resulting in a 50+ basis points increase in market share. ➠ Orchestrated the rollout of the "Fuel the Wonder" campaign, establishing a best-in-class communication framework across the portfolio. ➠ Designed and implemented a comprehensive HCP engagement strategy, tailored to advocacy levels and specialties, to drive portfolio alignment and market impact. ➠ Launched an innovative CME strategy, including the "FIRST Nurse's Program," achieving a 50%+ expansion in reach and advocacy. ➠ Optimized Mum's CRM program, driving a threefold increase in conversion rates and enhancing consumer engagement and loyalty.

➠ Directed the OTC portfolio for developing markets, valued at £212M, including global brands such as Strepsils, Gaviscon, and Nurofen, while managing the South African OTC market (£33M) with local flagship brands like Disprin, Transact, and Strepsils. ➠ Spearheaded the turnaround of Strepsils, driving +12% revenue growth and achieving a 120-basis-point market share increase, while accelerating the growth of Gaviscon and Nurofen with a combined 18% revenue growth and a 250-basis-point market share gain. ➠ Developed strategic playbooks for Strepsils and Gaviscon to identify new usage occasions and expand market penetration. ➠ Designed and executed impactful communication strategies across the portfolio, enhancing overall brand equity by 80 basis points. ➠ Resolved trade execution challenges within the Pharmacy channel, addressing key discrepancies and optimizing performance.

➠ Managed the Strepsils brand, valued at £95.2M, across 22 key developing markets, delivering strong performance improvements. ➠ Revitalized brand performance, achieving 16.4% net revenue growth in 2016 and a 54-basis-point market share gain, reversing two years of share decline through the successful rollout of the Versatility campaign. ➠ Developed and executed the DvM (Developing Markets) strategy for Strepsils, including: - Creating a strategic communication roadmap using a clustering approach (Sweets and Medicine clusters). - Identifying and leveraging non-infectious inflection points to enhance relevance and drive consumption.

➠ Managed leading brands across key healthcare categories, including Disprin, D'cold (Lemsip), Strepsils, Gaviscon, and Mucinex, leveraging robust medical marketing and consumer engagement strategies to drive growth. ➠ Delivered consecutive growth for Strepsils, achieving a 27% increase in 2014 and 18% in 2013 through targeted campaigns and strategic market interventions. ➠ Successfully developed and executed the Local Success Model for Gaviscon in India, initiating a pilot launch in Tamil Nadu, followed by a nationwide rollout after its successful performance in Q4 2013.

➠ Achieved a 15% increase in regional sales as a Regional Manager through effective sales strategies and market expansion initiatives. ➠ Improved prescription share by 400 basis points as a Senior Brand Manager by implementing targeted strategies and building strong healthcare professional relationships. ➠ Delivered a 28% revenue growth in the BPH (Benign Prostatic Hyperplasia) segment through strategic engagement and execution with healthcare professionals.

Artificial Intelligence : Business Strategies and Applications